동물용 구충제 시장 : 유형별, 동물 유형별, 용도별, 기생충 유형별, 유통 채널별, 최종사용자별 - 세계 예측(2025-2032년)

The Veterinary Parasiticides Market is projected to grow by USD 15.18 billion at a CAGR of 7.98% by 2032.

Concise orientation to the contemporary veterinary parasiticides environment shaped by animal health priorities, regulatory rigor, and technological momentum

The global veterinary parasiticides arena stands at the intersection of animal welfare expectations, evolving regulatory standards, and accelerated scientific innovation. Over recent years, stakeholders across companion and production animal sectors have prioritized effective parasite control as a cornerstone of health management, productivity, and One Health stewardship. This emphasis has intensified as pet ownership patterns shift, livestock systems modernize, and awareness grows around zoonotic risks that link animal parasitic burdens to broader public health outcomes.

Investment in next-generation chemistries, biologics, and delivery systems has been matched by greater scrutiny from regulatory bodies and a more sophisticated veterinary community demanding safety, efficacy, and sustainability. Simultaneously, the industry is adapting to supply chain realignments, digital distribution channels, and an expanding role for data-driven veterinary services. These forces combine to create both challenges and opportunities for manufacturers, distributors, and veterinary practitioners aiming to meet rising expectations while navigating cost pressures and resistance management imperatives.

Given this dynamic backdrop, executives and practitioners need a clear, evidence-based synthesis of technological trajectories, regulatory signals, and commercial pathways. A careful appraisal of these factors supports informed decisions about product portfolios, strategic partnerships, and investment in innovation that deliver measurable animal health outcomes and durable competitive advantage.

How technological innovation, distribution evolution, and stewardship pressures are jointly transforming research, commercialization, and lifecycle strategies in parasiticides

Transformative shifts are reshaping the veterinary parasiticide landscape at multiple layers, from discovery platforms to end-user interactions. Advances in molecular biology and target-based screening have accelerated identification of novel modes of action, while formulation science has enabled sustained-release, reduced-dosing, and precision-delivery approaches. These technological innovations are complemented by digital tools that enhance treatment adherence, enable remote monitoring of animal health, and support data-driven resistance surveillance.

Concurrently, the industry is experiencing structural shifts in distribution and customer engagement. Ecommerce and tele-veterinary services have expanded access to products and expertise, especially among urban pet owners and geographically dispersed producers. Fragmentation within distribution channels is prompting incumbent firms to pursue integrated solutions that bundle diagnostic, therapeutic, and advisory services. Moreover, heightened regulatory scrutiny and stronger pharmacovigilance expectations are driving investments in post-market surveillance and evidence generation to support product lifecycle strategies.

Finally, there is a palpable movement toward sustainability and stewardship. Integrated parasite management programs that combine chemical, biological, and management interventions are gaining traction, reflecting an acknowledgment that long-term efficacy depends on preserving antiparasitic effectiveness while minimizing environmental and residue concerns. Together, these shifts indicate an industry transitioning from commodity product supply toward value-added, outcome-oriented offerings.

Assessment of how recent tariff adjustments and trade policy dynamics in 2025 are reshaping sourcing, supply resilience, and strategic manufacturing decisions

The cumulative effect of tariff adjustments and trade policy shifts in 2025 is prompting a strategic reassessment across sourcing, pricing, and supply continuity for veterinary parasiticides. Companies that rely on cross-border procurement of active pharmaceutical ingredients or finished formulations are evaluating supplier diversification and onshoring options to mitigate exposure to tariff volatility. In parallel, procurement teams are recalibrating costing models to reflect additional duties, logistical friction, and potential pass-through to end users, while also seeking long-term agreements and hedging mechanisms to stabilize input costs.

These trade-related headwinds are accelerating conversations about regional manufacturing capacity and strategic inventory positioning. Firms are exploring localized production hubs and contract manufacturing partnerships to shorten supply chains and reduce tariff impacts. At the same time, distributors and retailers are reassessing assortment strategies to balance imported premium products with locally sourced alternatives that present lower tariff risk and faster replenishment cycles.

Policy changes have also influenced investment planning, as companies weigh the capital requirements of new manufacturing footprints against the commercial benefits of tariff mitigation. In response, many organizations are prioritizing portfolio rationalization and selective innovation investments that promise higher margin resilience. Overall, the tariff environment in 2025 has underscored the need for more agile supply chain design and proactive trade risk management across the veterinary parasiticide value chain.

Deep segmentation insights that align therapeutic formulation, delivery mode, and distribution strategies to the diverse needs of animal types and end users

Effective segmentation is critical for aligning product development and commercial strategies with distinct needs across therapeutic and customer categories. Based on Type, the landscape includes ectoparasiticides, endectocides, and endoparasiticides, each requiring differentiated efficacy data and resistance management profiles. Based on Animal Type, stakeholders must address divergent use patterns between companion animals and livestock animals; companion animals require formulations and dosing considerations across birds, cats, dogs, and reptiles, while livestock applications span cattle, poultry, sheep and goats, and swine, each with unique production contexts and withdrawal considerations.

Based on Mode Of Application, the industry must balance preferences and constraints among injectable administration, oral administration, and topical administration, with each mode presenting trade-offs in compliance, pharmacokinetics, and practical administration in field settings. Based on Parasite Type, formulation and surveillance priorities are guided by target parasites such as cestodes, ectoparasites, nematodes, and trematodes, driving the need for combination therapies and diagnostics that can inform targeted interventions. Based on Distribution Channel, the channel mix between offline retail and online retail influences marketing, regulatory compliance, and customer support models. Based on End-User, product positioning must reflect the differing requirements of animal farms, household pet owners, and veterinary hospitals, with the Animal Farms segment further differentiated into dairy farms, poultry farms, and swine farms where operational scale and biosecurity practices affect purchasing decisions.

Taken together, this segmentation framework supports more precise value propositions, tailored evidence packages, and channel strategies that respond to the heterogeneous demands across therapeutic categories and user types.

Regional dynamics and differentiated strategies across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence regulation, distribution, and product adoption

Regional dynamics shape regulatory regimes, distribution infrastructures, and product preferences, requiring nuanced geographic strategies. In the Americas, demand patterns are influenced by mature companion animal markets, well-established veterinary channels, and growing emphasis on integrated parasite control programs; regulatory systems tend to emphasize rigorous efficacy and safety data, and private veterinary networks play a central role in product adoption. In Europe, Middle East & Africa, regulatory harmonization across jurisdictions, heightened environmental scrutiny, and diverse agricultural systems create a mosaic of opportunities and constraints; producers in some regions prioritize residue avoidance and sustainability while others focus on rapid productivity gains.

In Asia-Pacific, rapidly expanding companion animal ownership and intensive livestock production systems are driving strong demand for effective parasiticides, with local manufacturing and generic competitiveness shaping price expectations. Across all regions, digital distribution and telehealth-enabled advisory services are gaining traction, though adoption rates vary with infrastructure and regulatory allowances. Additionally, regional differences in parasite prevalence, climatic factors, and farming practices necessitate tailored product portfolios and region-specific resistance management strategies. These geographic distinctions underscore the importance of adaptive regulatory engagement, regional supply chain design, and culturally appropriate customer education initiatives to maximize uptake and ensure responsible use.

Insights into how leading firms combine innovation, partnerships, and service-oriented commercial models to strengthen competitiveness and stewardship

Leading companies in the veterinary parasiticide space are converging on strategies that emphasize differentiated pipelines, strategic partnerships, and enhanced service offerings. Several organizations are investing in novel chemistries and biologic approaches to address resistance hotspots, while others are prioritizing formulation and delivery innovations that improve adherence and animal welfare. Strategic alliances with contract manufacturers, diagnostic providers, and digital health platforms are increasingly common, enabling faster route-to-market for combination solutions that bundle therapeutics with diagnostic and advisory services.

Competitive positioning is also shaped by investments in regulatory science and post-market evidence generation, as demonstrated safety and longitudinal efficacy data become essential differentiators. Companies that integrate stewardship programs, training for veterinarians and farm managers, and clear residue management guidance are better placed to sustain long-term customer trust. Moreover, commercial models are evolving; players that offer subscription-like services, outcome-based contracts, or integrated farm health packages can capture deeper customer relationships and stabilize revenue streams. Across the landscape, successful firms are those that pair technical excellence with pragmatic commercial execution, thereby aligning innovation with real-world veterinary practice and farm management needs.

Actionable strategic priorities and operational measures that industry leaders should implement to enhance resilience, innovation, and responsible product adoption

Industry leaders should prioritize a set of pragmatic actions to navigate current challenges and seize emerging opportunities. First, invest in diversified supplier networks and regional manufacturing capabilities to reduce exposure to trade disruptions and tariffs while maintaining quality controls. Second, accelerate R&D that targets novel modes of action and improved delivery systems to address resistance and improve compliance, while also expanding post-market evidence programs to demonstrate long-term safety and performance. Third, develop integrated offerings that combine therapeutics with diagnostics, digital monitoring, and advisory services, thereby shifting conversations from single-product sales to holistic animal health outcomes.

Furthermore, leaders should implement clear stewardship and education initiatives aimed at veterinarians, farm managers, and pet owners to promote responsible use and mitigate resistance development. Collaborating on multi-stakeholder surveillance efforts will enhance the evidence base and inform targeted interventions. Commercially, firms must refine channel strategies to balance offline and online retail strengths, while experimenting with subscription models and bundled services to capture recurring revenue. Finally, adopt scenario-based supply chain planning and flexible contracting to reduce tariff and logistical risk, and allocate capital to partnerships and M&A that accelerate access to complementary capabilities and regional market presence.

Transparent and rigorous research methodology combining stakeholder engagement, secondary evidence review, and scenario analysis to validate findings and implications

The research underpinning these insights integrates multiple qualitative and quantitative approaches to ensure rigor and relevance. Primary engagements included structured interviews with veterinarians, farm managers, regulatory specialists, and commercial leaders to capture real-world perspectives on efficacy, adoption barriers, and procurement dynamics. Secondary analysis encompassed peer-reviewed literature, regulatory guidance documents, clinical trial registries, and publicly available corporate disclosures to validate technological trends and regulatory shifts. Additionally, supply chain and trade databases were examined to understand sourcing patterns and tariff exposure, while digital analytics were used to assess consumer engagement and channel evolution.

Methodologically, triangulation across data sources and stakeholder perspectives was used to reduce bias, and findings were stress-tested through scenario analysis to account for tariff volatility and regulatory contingency. Where applicable, case examples illustrate how specific innovations and commercial models have been implemented in practice, and methodological appendices document inclusion criteria, interview protocols, and data provenance for transparency. This layered approach ensures that the conclusions presented are grounded in observable industry behavior and robust stakeholder input.

Concluding synthesis of the prevailing trends that signal a structural shift toward integrated solutions, resilience, and stewardship in parasiticide practice

In summary, the veterinary parasiticide ecosystem is undergoing sustained transformation driven by scientific innovation, changing distribution and consumption patterns, and heightened regulatory and stewardship expectations. These dynamics are fostering a shift from product-centric approaches toward integrated, outcome-focused solutions that pair therapeutics with diagnostics, digital services, and advisory support. Simultaneously, trade policy changes and supply chain complexities are prompting strategic realignment in sourcing and manufacturing decisions, emphasizing resilience and regional adaptability.

For stakeholders across the value chain, the imperative is clear: align R&D, commercial, and operational strategies with evolving end-user needs and regulatory realities. Prioritizing stewardship, investing in differentiated delivery mechanisms, and embracing flexible distribution models will be critical to maintaining efficacy, protecting animal welfare, and unlocking commercial value. Looking ahead, organizations that effectively integrate technical innovation with pragmatic market strategies and robust supply chain planning will be best positioned to lead in a more demanding and opportunity-rich environment.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Growing adoption of isoxazoline-based chewable formulations for canine flea and tick control
• 5.2. Rising prevalence of macrocyclic lactone resistance in canine heartworm populations due to prophylactic overuse
• 5.3. Development of topical endectocide combination therapies to address multi-parasite infestations in equine practice
• 5.4. Expansion of oral sustained-release flea collar technology for extended pest management in feline patients
• 5.5. Implementation of digital diagnostics and remote dispensing for precision parasite control in livestock operations
• 5.6. Regulatory approvals accelerating novel moxidectin and eprinomectin formulations for small ruminant parasite management
• 5.7. Innovations in nanoparticle carrier systems enhancing bioavailability of veterinary antiparasitic compounds in cattle
• 5.8. Integration of telemedicine platforms for real-time monitoring and targeted deworming in high-value breeding herds

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Veterinary Parasiticides Market, by Type

• 8.1. Ectoparasiticides
• 8.2. Endectocides
• 8.3. Endoparasiticides

9. Veterinary Parasiticides Market, by Animal Type

• 9.1. Companion Animals
  • 9.1.1. Birds
  • 9.1.2. Cats
  • 9.1.3. Dogs
  • 9.1.4. Reptiles
• 9.2. Livestock Animals
  • 9.2.1. Cattle
  • 9.2.2. Poultry
  • 9.2.3. Sheep & Goats
  • 9.2.4. Swine

10. Veterinary Parasiticides Market, by Mode Of Application

• 10.1. Injectable Administration
• 10.2. Oral Administration
• 10.3. Topical Administration

11. Veterinary Parasiticides Market, by Parasite Type

• 11.1. Cestodes
• 11.2. Ectoparasites
• 11.3. Nemotodes
• 11.4. Trematodes

12. Veterinary Parasiticides Market, by Distribution Channel

• 12.1. Offline Retail
• 12.2. Online Retail

13. Veterinary Parasiticides Market, by End-User

• 13.1. Animal Farms
  • 13.1.1. Dairy Farms
  • 13.1.2. Poultry Farms
  • 13.1.3. Swine Farms
• 13.2. Household Pet Owners
• 13.3. Veterinary Hospitals

14. Veterinary Parasiticides Market, by Region

• 14.1. Americas
  • 14.1.1. North America
  • 14.1.2. Latin America
• 14.2. Europe, Middle East & Africa
  • 14.2.1. Europe
  • 14.2.2. Middle East
  • 14.2.3. Africa
• 14.3. Asia-Pacific

15. Veterinary Parasiticides Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Veterinary Parasiticides Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Share Analysis, 2024
• 17.2. FPNV Positioning Matrix, 2024
• 17.3. Competitive Analysis
  • 17.3.1. AB Vista Inc.
  • 17.3.2. Alltech Inc.
  • 17.3.3. Ashish Life Science Pvt Limited
  • 17.3.4. Aurora Pharmaceutical, Inc.
  • 17.3.5. Bayer AG
  • 17.3.6. Bimeda Inc.
  • 17.3.7. Bioiberica, S.A.
  • 17.3.8. Boehringer Ingelheim International GmbH
  • 17.3.9. Cargill Inc.
  • 17.3.10. Ceva Sante Animale
  • 17.3.11. Covetrus Inc.
  • 17.3.12. Dechra Pharmaceuticals Plc
  • 17.3.13. Elanco Animal Health Incorporated
  • 17.3.14. Indian Immunologicals Limited
  • 17.3.15. Jurox Animal Health Ltd.
  • 17.3.16. Merck & Co., Inc.
  • 17.3.17. Neogen Corporation
  • 17.3.18. Norbrook Laboratories Ltd.
  • 17.3.19. PetIQ, LLC
  • 17.3.20. Vetaid Animal Health
  • 17.3.21. VetGuard Inc.
  • 17.3.22. Vetoquinol S.A.
  • 17.3.23. Vetsafe Ltd.
  • 17.3.24. Virbac Corporation
  • 17.3.25. Zhejiang Hisun Pharmaceutical Co., Ltd.
  • 17.3.26. Zoetis Inc.